Breath and Urine Tests Detect Early Breast Cancer
By LabMedica International staff writers Posted on 08 May 2018 |
Image: A diagram of breast cancer detection using artificial neural network (Photo courtesy of Ben-Gurion University).
Breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world. In 2016, breast cancer accounted for 29% of all new cancers identified in the USA and was responsible for 14% all cancer-related deaths.
Current diagnostic imaging detection for smaller tumors has significant drawbacks: dual-energy digital mammography, while effective, increases radiation exposure, and magnetic resonance imaging (MRI) is expensive. Biopsies and serum biomarker identification processes are invasive, equipment-intensive and require significant expertise.
Scientists at the Ben-Gurion University of the Negev (Beersheba, Israel) collected exhaled breath samples from 48 breast cancer (BC) patients and 45 healthy women that served as a control group. Urine samples were collected from 37 patients who were diagnosed with BC based on physical or mammography tests prior to any surgery, and from 36 healthy women. Two commercial electronic noses (ENs) were used for the exhaled breath analysis. Urine samples were analyzed using Gas-Chromatography Mass-Spectrometry (GC-MS).
Statistical analysis of results was based on an artificial neural network (ANN) obtained following feature extraction and feature selection processes. The model obtained allows classification of breast cancer patients with an accuracy of 95.2% ± 7.7% using data of one EN, and an accuracy of 85% for the other EN and for urine samples.
The authors concluded that the developed statistical analysis method enables accurate classification of patients as healthy or with BC based on simple non-invasive exhaled breath and a urine sample analysis. This study demonstrates that available commercial ENs can be used, provided that the data analysis is carried out using an appropriate method.
Yehuda Zeiri, PhD, a professor of Biomedical Engineering and senior author of the study said, “Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.” The study was published on May 1, 2018, in the journal Computers in Biology and Medicine.
Related Links:
Ben-Gurion University of the Negev
Current diagnostic imaging detection for smaller tumors has significant drawbacks: dual-energy digital mammography, while effective, increases radiation exposure, and magnetic resonance imaging (MRI) is expensive. Biopsies and serum biomarker identification processes are invasive, equipment-intensive and require significant expertise.
Scientists at the Ben-Gurion University of the Negev (Beersheba, Israel) collected exhaled breath samples from 48 breast cancer (BC) patients and 45 healthy women that served as a control group. Urine samples were collected from 37 patients who were diagnosed with BC based on physical or mammography tests prior to any surgery, and from 36 healthy women. Two commercial electronic noses (ENs) were used for the exhaled breath analysis. Urine samples were analyzed using Gas-Chromatography Mass-Spectrometry (GC-MS).
Statistical analysis of results was based on an artificial neural network (ANN) obtained following feature extraction and feature selection processes. The model obtained allows classification of breast cancer patients with an accuracy of 95.2% ± 7.7% using data of one EN, and an accuracy of 85% for the other EN and for urine samples.
The authors concluded that the developed statistical analysis method enables accurate classification of patients as healthy or with BC based on simple non-invasive exhaled breath and a urine sample analysis. This study demonstrates that available commercial ENs can be used, provided that the data analysis is carried out using an appropriate method.
Yehuda Zeiri, PhD, a professor of Biomedical Engineering and senior author of the study said, “Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.” The study was published on May 1, 2018, in the journal Computers in Biology and Medicine.
Related Links:
Ben-Gurion University of the Negev
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes